Drug Detail

Information about brivanib alaninate

Generic Name	brivanib alaninate
IND	BMS-582664
Brand Name (US)
Manufacturer	Bristol-Myers Squibb
Drug Type	Tyrosine Kinase Inhibitor
Delivery
Approval Status	Phase 3
Indications
Overall Strategy	GIST Tumor Based
Strategy	Block tumor blood vessel growth
Drug Category	VEGFR inhibitor (TKI)

The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.
Brivanib is also reported to inhibit FGFR.

Leiomyosarcoma listserve patients report being in a trial of this drug 3/11/09 TJH